Research published this week indicates that GLP-1 medications, such as semaglutide and tirzepatide, may be associated with side effects including hair loss and nail problems. A study conducted by scientists in Europe analyzed data from hundreds of individuals using GLP-1 medications and found that these users were significantly more likely to experience hair loss and nail-related issues, particularly nail detachment, compared to non-users. The researchers emphasized that while these side effects are not typically severe, both patients and healthcare providers should be aware of the potential risks.
Charles Taïeb, a clinical dermatologist at Necker University Hospital in Paris and author of the study, advised individuals taking or considering GLP-1 receptor agonists to remain calm and not discontinue treatment without consulting a doctor if they experience hair or nail symptoms. The Food and Drug Administration (FDA) has mandated that GLP-1 drugs like Ozempic (semaglutide) and Zepbound (tirzepatide) include alopecia as a potential adverse reaction on their labeling, following investigations into post-market data.
The SCOP-GLP1 research team, consisting of scientists from France and Italy, conducted two studies comparing 575 GLP-1 users to 1,379 controls who had not started GLP-1 therapy. Participants were selected from a representative sample across four countries: France, the United States, Brazil, and Mexico. The average treatment duration was 18.5 months, and weight changes were monitored over three months.
The findings revealed that approximately 50% of GLP-1 users reported unusual hair loss, compared to about one-third of control participants. Additionally, 66% of GLP-1 users reported general nail problems, with 39% experiencing nail detachment, compared to 9% of controls. Nail discoloration was reported by 46% of GLP-1 users versus 17% of non-users.
The studies were presented at the annual conference of the European Academy of Dermatology and Venereology and have not yet undergone formal peer review. Taïeb noted that the research does not establish causation but highlights the need for further investigation. Future studies will aim to follow individuals starting GLP-1 therapy and objectively assess their skin and hair health over time.
The researchers found that preexisting health conditions and nutritional deficiencies may better explain some nail issues rather than the GLP-1 drugs themselves. Taïeb suggested that patients and clinicians should monitor scalp health and nail changes in the context of overall health, rather than attributing these issues solely to the medication. Persistent nail detachment should be evaluated by a dermatologist.